🇺🇸 FDA
Pipeline program

NTQ5082 capsule

NTQ5082-24102

Phase 1 small_molecule active

Quick answer

NTQ5082 capsule for Complement-mediated Hemolytic Diseases is a Phase 1 program (small_molecule) at Nanjing Chia-tai Tianqing Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Nanjing Chia-tai Tianqing Pharmaceutical
Indication
Complement-mediated Hemolytic Diseases
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials